A recent study demonstrated that the knockout of the transcription factor AT-rich interactive domain-containing protein 3A (ARID3A) can inhibit tumor progression in pancreatic cancer and enhance the sensitivity of cells to gemcitabine. This evidence concerns the gene ARID3A and neoplasm.